Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial

MT newswire2026/10/09 08:09

04:09 AM EDT, 10/09/2026 (MT Newswires) -- Pharvaris (PHVS) said Thursday the phase 3 study of its experimental drug, deucrictibant, for on-demand treatment of hereditary angioedema attacks met its main and all 11 secondary goals. The study showed that deucrictibant stopped symptoms from worsening, relieved symptoms and achieved complete symptom resolution significantly faster than placebo, the company said. The company said the US Food and Drug Administration is reviewing its application, with a decision expected by April 23, 2027. The European Medicines Agency is also reviewing its marketing application, it added.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37